Presentation is loading. Please wait.

Presentation is loading. Please wait.

GDF-15 levels in progressors and nonprogressors in albuminuria (case and control subjects) for patients with T2DM and nondiabetic patients with HT. A:

Similar presentations


Presentation on theme: "GDF-15 levels in progressors and nonprogressors in albuminuria (case and control subjects) for patients with T2DM and nondiabetic patients with HT. A:"— Presentation transcript:

1 GDF-15 levels in progressors and nonprogressors in albuminuria (case and control subjects) for patients with T2DM and nondiabetic patients with HT. A: GDF-15 levels (pg/mL) (mean ± SE) in progressors and nonprogressors in albuminuria for T2DM and HT. B: GDF-15 levels (pg/mL) (mean ± SE) in progressors and nonprogressors in albuminuria for T2DM and HT stratified for baseline albuminuria (normoalbuminuria [Normo] or microalbuminuria [Micro]); *P < 0.05, **P < GDF-15 levels in progressors and nonprogressors in albuminuria (case and control subjects) for patients with T2DM and nondiabetic patients with HT. A: GDF-15 levels (pg/mL) (mean ± SE) in progressors and nonprogressors in albuminuria for T2DM and HT. B: GDF-15 levels (pg/mL) (mean ± SE) in progressors and nonprogressors in albuminuria for T2DM and HT stratified for baseline albuminuria (normoalbuminuria [Normo] or microalbuminuria [Micro]); *P < 0.05, **P < Macro, macroalbuminuria. Merel E. Hellemons et al. Dia Care 2012;35: ©2012 by American Diabetes Association


Download ppt "GDF-15 levels in progressors and nonprogressors in albuminuria (case and control subjects) for patients with T2DM and nondiabetic patients with HT. A:"

Similar presentations


Ads by Google